Efficacy and tolerability of quetiapine in patients with schizophrenia switched from other antipsychotics

REFERENCES

• Kane J (2001) Progress defined — short-term efficacy, long-term effectiveness. Int Clin Psychopharmacol 16(Suppl 1): S1–8.
   Web of Science ®Google Scholar
• Jibson MD, Tandon R (1998) New atypical antipsychotic medications. J Psychiatr Res 32: 215–28.
   PubMed Web of Science ®Google Scholar
• Stanniland C, Taylor D (2000) Tolerability of atypical antipsychotics. Drug Saf 22: 195–214.
   PubMed Web of Science ®Google Scholar
• Emsley RA (1999) Partial response to antipsychotic treatment: the patient with enduring symptoms. J Clin Psychiatry 60(Suppl 23): 10–3.
   Web of Science ®Google Scholar
• Weiden PJ, Aquila R, Dalheim L, Standard JM (1997) Switching antipsychotic medications. J Clin Psychiatry 58(Suppl 10): 63 — 72.
   Google Scholar
• Kane JM (2001) Extrapyramidal side effects are unacceptable. Eur Neuropsychopharmacol 11(Suppl 4): S397–403.
   Google Scholar
• Arana GW (2000) An overview of side effects caused by typical antipsychotics. J Clin Psychiatry 61(Suppl 8): 5 — 11.
   Google Scholar
• Emsley RA, Raniwalla J, Bailey PJ, Jones AM, on behalf of the PRIZE Study Group (2000) A comparison of the effects of quetiapine (‘Seroquel’) and haloperidol in schizophrenic patients with a history of and a demonstrated, partial response to conventional antipsychotic treatment. Int Clin Psychopharmacol 15: 121—31.
   Google Scholar
• Kane JM, Marder SR, Schooler NR et al (2001) Clozapine and haloperidol in moderately refractory schizophrenia: a 6-month randomized and double-blind comparison. Arch Gen Psychiatry 58: 965—72.
   Google Scholar
• Masand PS, Berry SL (2000) Switching antipsychotic therapies. Ann Pharmacother 34: 200–7.
   PubMed Web of Science ®Google Scholar
• Barnes TRE, Joyce EM (2001) Antipsychotic drug treatment: recent advances. Curr Opin Psychiatry 14: 25–37.
   Web of Science ®Google Scholar
• Cutler AJ, Goldstein JM, Tumas JA (2002) Dosing and switching strategies for quetiapine fumarate. Clin Ther 24: 209—22.
   PubMed Web of Science ®Google Scholar
• Arvanitis LA, Miller BG, and the Seroquel Trial 13 study group (1997) Multiple fixed doses of ‘‘Seroquel’’ (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 42: 233—46.
   Google Scholar
• Borison RL, Arvanitis LA, Miller BG, the US Seroquel Study Group (1996) ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. J Clin Psychopharmacol 16: 158–69.
   PubMed Web of Science ®Google Scholar
• Small JG, Hirsch SR, Arvanitis LA et al (1997) Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry 54: 549–57.
   PubMed Web of Science ®Google Scholar
• Kasper S, Müller-Spahn F (2000) Review of quetiapine and its clinical applications in schizophrenia. Expert Opin Pharmacother 1: 783–801.
   PubMedGoogle Scholar
• Brecher M, Rak IW, Westhead EK, Jones AM (2000) The long-term effect of quetiapine (SeroquelTM) monotherapy on weight in patients with schizophrenia. IntJ Psychiatry Clin Pract 4: 287–91.
   PubMed Web of Science ®Google Scholar
• Still DJ, Dorson PG, Crismon ML, Pousson C (1996) Effects of switching inpatients with treatment-resistant schizophrenia from clozapine to risperidone. Psychiatr Serv 47: 1382—4.
   PubMed Web of Science ®Google Scholar
• Henderson DC, Nasrallah RA, Goff DC (1998) Switching from clozapine to olanzapine in treatment-refractory schizophrenia: safety, clinical efficacy, and predictors of response. J Clin Psychiatry 59: 585—8.
   PubMed Web of Science ®Google Scholar
• Tollefson GD, Dellva MA, Mattler CA et al (1999) Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. J Clin Psychopharmacol 19: 435–43.
   Google Scholar
• Dossenbach MR, Kratky P, Schneidman M et al (2001) Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone. J Clin Psychiatry 62(Suppl 2): 28–34.
   Google Scholar
• Klieser E, Lehmann E, Kinzler E et al (1995) Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with chronic schizophrenia. J Clin Psychopharmacol 15: 45S-51S.
   Google Scholar
• Tran PV, Hamilton SH, Kuntz AJ et al (1997) Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 17: 407–18.
   PubMed Web of Science ®Google Scholar
• Conley RR, Mahmoud R (2001) A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. AmJ Psychiatry 58: 765—74.
   Google Scholar
• Mullen J, Jibson MD, Sweitzer D (2001) A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study. Clin Ther 23: 1839–54.
   PubMed Web of Science ®Google Scholar
• Seroquel prescribing information (2001). 1—25.
   Google Scholar